Home » Newsletters » BioWorld Science

BioWorld Science

June 19, 2000

View Archived Issues

Chiron and Norwegian National Institutes of Public Health formalize meningitis agreement

Pivotal trials of Cangene human growth hormone begin

Genmab completes financing round; company to accelerate human antibody therapeutics development

Millennium submits IND application for ulcerative colitis treatment to FDA

Ibis Therapeutics and Agouron embark on drug discovery collaboration

Gilead begins another multinational phase III trial of once-daily oral anti-HIV drug

MorphoSys licenses HuCAL technology to Eos Biotechnology

New NHLBI study to identify best treatment for mild persistent asthma

Nexell obtains exclusive license to Diaclone antibody portfolio

Serono and PowderJect achieve development milestone

Nastech reports pilot phase I trial results for new formulation of butorphanol

Interneuron licenses rights to PRO-2000

JTT-501 improves insulin resistance and exerts antidiabetic effects with less weight gain

Improvement in insulin sensitivity demonstrated for WAY-123783 in model of severe insulin resistance

Modified CNTF improves glucose tolerance and insulin-dependent signaling in db/db mice

Phase II trial of Genentech's anti-CD18 antibody fails to meet primary objectives

Data from primate and early clinical studies on oral DPP-IV inhibitor presented at ADA meeting

Seretide MDI approved in the U.K. for asthma Rx

Roche seeks approval for Tamiflu pediatric indication

Intermittent neridronate effective in bone disorders and rheumatoid arthritis

Vitamin D3 derivatives synthesized at Teijin, particularly useful for airways diseases

New PDE4/TNF inhibitors with superior physicochemical and pharmacokinetic profile

R.J. Reynolds presents new amine nicotinic acetylcholine receptor agonists

Potent and selective COX-2 inhibitors from Chugai

Immunosuppressive 2-acylquinolines developed by Japanese lab

Neurocrine Biosciences patents new CRF antagonists

LHRH (GnRH) analogue useful for osteoporosis and other bone disorders

Aventis describes production and activity of new antibiotic

Novel Roche compounds for MMP-related diseases

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...